Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2026-03-03 @ 8:41 AM
Study NCT ID:
NCT03899805
Status:
COMPLETED
Last Update Posted:
2025-08-28
First Post:
2019-04-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-04
Start Date Type:
ACTUAL
Primary Completion Date:
2024-07-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-07-16
Completion Date Type:
ACTUAL
First Submit Date:
2019-04-01
First Submit QC Date:
None
Study First Post Date:
2019-04-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-07-16
Results First Submit QC Date:
None
Results First Post Date:
2025-08-28
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-11
Last Update Post Date:
2025-08-28
Last Update Post Date Type:
ESTIMATED